Developing and externally validating multinomial prediction models for methotrexate treatment outcomes in patients with rheumatoid arthritis: Results from an international collaboration

Celina Gehringer, Glen Martin, Kimme Hyrich, Suzanne Verstappen, Joseph Sexton, Eirik K. Kristianslund, Sella A. Provan, Tore K Kvien, Jamie Sergeant

Research output: Contribution to journalArticlepeer-review

Abstract

Objectives: In rheumatology, there is a clinical need to identify patients at high risk (>50%) of not responding to the first-line therapy methotrexate (MTX) due to lack of disease control or discontinuation due to adverse events (AEs). Despite this need, previous prediction models in this context are at high risk of bias and ignore AEs. Our objectives were to (i) develop a multinomial model for outcomes of low disease activity (LDA) and discontinuing due to AEs 6 months after starting MTX, (ii) update prognosis 3-months following treatment initiation, and (iii) externally validate these models.
Study Design and Setting: A multinomial model for LDA (submodel 1) and discontinuing due to AEs (submodel 2) was developed using data from the UK Rheumatoid Arthritis Medication Study, updated using landmarking analysis, internally validated using bootstrapping, and externally validated in the Norwegian Disease-Modifying Antirheumatic Drug register (NOR-DMARD). Performance was assessed using calibration (calibration-slope, calibration-in-the-large), and discrimination (concordance-statistic, polytomous discriminatory index).
Results: The internally validated model showed good calibration in the development setting with a calibration-slope of 1.01 (0.87, 1.14) (submodel 1) and 0.83 (0.30, 1.34) (submodel 2), and moderate discrimination with a c-statistic of 0.72 (0.69, 0.74) and 0.53 (0.48, 0.59), respectively. Predictive performance decreased after external validation (calibration-slope 0.78 (0.64, 0.93) (submodel 1) and 0.86 (0.34, 1.38) (submodel 2)), which may be due to differences in disease-specific characteristics and outcome prevalence.
Conclusions: We addressed previously identified methodological limitations of prediction models for outcomes of MTX therapy. The multinomial approach predicted outcomes of disease activity more accurately than AEs, which should be addressed in future work to aid implementation into clinical practice.
Original languageEnglish
JournalJournal of Clinical Epidemiology
Publication statusAccepted/In press - 5 Dec 2023

Keywords

  • multinomial prediction model
  • calibration
  • external validation
  • risk prediction
  • recalibration
  • methotrexate

Fingerprint

Dive into the research topics of 'Developing and externally validating multinomial prediction models for methotrexate treatment outcomes in patients with rheumatoid arthritis: Results from an international collaboration'. Together they form a unique fingerprint.

Cite this